The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICLE 2022 | Relapsing from CAR T-cells in multiple myeloma
Tuna Mutis, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, describes mechanisms of resistance to chimeric antigen receptor (CAR) T-cell therapies in patients with multiple myeloma, including antigen escape and T-cell exhaustion. Certain targets such as B-cell maturation antigen (BCMA) may also not be highly expressed in the plasma cells of patients, reducing the efficacy of the treatment, and the quality of T-cells derived from patients may not be of standard. The tumor microenvironment additionally contributes to resistance to cell therapies, where their cytotoxicity may be reduced. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
